文献速递乳腺癌放疗放疗物理与技术

保乳治疗中全乳照射与术中电子线放疗比较:单机构大样本成熟配对评估真局部复发、无进展生存和总生存

Whole Breast Irradiation Versus Intraoperative Electron Radiation Therapy for Breast Conserving Therapy: A Large Mature Single Institution Matched-Pair Evaluation of True Local Relapse, Progression Free Survival, and Overall Survival.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-02-01

单机构配对研究比较258例术中电子线放疗(IOERT)与258例全乳照射(WBI)患者,中位随访约157个月。IOERT组同侧乳腺复发和真局部复发累积发生率均高于WBI组(P=.02),总生存、无病生存、第二肿瘤和心脏事件无差异。作者认为严格筛选患者时IOERT或可替代WBI,但需告知同侧复发风险可能增加。

要点

  • IOERT组同侧乳腺复发15年累积发生率为12.7%,WBI组为5.0%(P=.02)。
  • IOERT组真局部复发15年累积发生率为8.3%,WBI组为2.5%(P=.02)。
  • 总生存、无病生存、第二肿瘤发生率和心脏事件两组间无差异。

核心结论

  • 在美国放射肿瘤学会(ASTRO)合适患者组中,IOERT后同侧复发和真局部复发率高于WBI,但未达统计学显著。
  • 作者认为严格筛选患者时IOERT或可替代WBI,但应仔细告知患者IOERT可能增加同侧复发率。
  • IOERT与WBI的第二肿瘤发生率和心脏事件无差异。

研究设计与样本

  • 单机构配对比较研究,258例2000至2010年接受术中电子线放疗(IOERT)的患者与258例术后接受全乳照射(WBI)的患者按年龄、组织学、肿瘤大小、分级、淋巴结状态、激素受体、辅助治疗类型、手术切缘和治疗日期配对。

主要发现

  • IOERT组中位随访157个月(范围12-251),WBI组中位随访154个月(范围31-246)。
  • 同侧乳腺复发5、10、15年累积发生率IOERT组为2.4%、7.9%、12.7%,WBI组为1.2%、4.1%、5.0%(P=.02)。
  • 真局部复发5、10、15年累积发生率IOERT组为1.6%、5.1%、8.3%,WBI组为0.4%、2.1%、2.5%(P=.02)。
  • 总生存、无病生存、第二肿瘤发生率和心脏事件两组间无差异。
  • 按2009年标准APBI合适组中,IOERT同侧乳腺复发5、10、15年累积发生率为0%、6.1%、7.3%,APBI不合适组为7.3%、13.3%、19.9%;WBI合适组为0%、2.0%、3.1%,不合适组为1.8%、3.9%、3.9%。

关键数值与推荐

  • 按2009年标准,APBI合适组IOERT同侧乳腺复发15年累积发生率为7.3%,APBI不合适组为19.9%;WBI合适组为3.1%,不合适组为3.9%。
  • 按2017年标准,APBI合适组IOERT同侧乳腺复发5、10、15年累积发生率为1.1%、6.2%、7.8%,APBI cautionary组为6.4%、13.3%、27.5%;WBI合适组为1.7%、4.1%、5.4%,cautionary组为0%、4.4%、4.4%。

临床怎么用

  • 作者认为严格筛选患者时IOERT或可替代WBI,但应仔细告知患者IOERT可能增加同侧复发率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Comparative outcome data after intraoperative radiation therapy and whole breast irradiation (WBI) for breast cancer at >10 years median follow-up are rare. We present a mature, single-institution, matched-pair comparison reporting survival and relapse rates in patients treated with either modality. METHODS AND MATERIALS: Complete data sets for 258 intraoperative electron radiation therapy (IOERT) patients treated between 2000 and 2010 were matched with 258 patients postoperatively treated with WBI by age/histology/tumor size, grading/lymph-node-status/hormone receptors/type of adjuvant therapy/surgical margins, and treatment date. Relapse at surgical intervention site was classified as true local recurrence (LR). All recurrences in the treated breast (any quadrant) were classified as ipsilateral recurrence (IR). RESULTS: Median follow-up was 157 months (12-251) for the IOERT group and 154 months (31-246) for the WBI group. Cumulative incidence of IR at 5, 10, and 15 years was 2.4%, 7.9%, and 12.7% for IOERT and 1.2%, 4.1%, and 5.0% for WBI (P = .02). Cumulative incidence of LR at 5, 10, and 15 years was 1.6%, 5.1%, and 8.3% for IOERT and 0.4%, 2.1%, and 2.5% for WBI (P = .02). No differences in overall survival, disease-free survival, second cancer incidence, or cardiac events were recorded in either treatment group. Outcome was better in the accelerated partial breast irradiation (APBI)-suitable group than in the APBI-unsuitable group (2009 criteria) (cumulative incidence of IR at 5, 10, and 15 years was 0% vs 7.3%, 6.1% vs 13.3%, and 7.3% vs 19.9% for IOERT and 0% vs 1.8%, 2.0% vs 3.9%, and 3.1% vs 3.9% for WBI) and in the revised APBI-suitable group than in the APBI-cautionary group (2017 criteria) (cumulative incidence of IR at 5, 10, and 15 years was 1.1% vs 6.4%, 6.2% vs 13.3%, and 7.8% vs 27.5% for IOERT and 1.7% vs 0%, 4.1% vs 4.4%, and 5.4% vs 4.4% for WBI). CONCLUSIONS: The IR and LR rate were higher after IOERT than after WBI for the American Society for Radiation Oncology suitable patient group, although without reaching statistical significance. Thus, IOERT could be an alternative to WBI upon stringent patient selection, but patients should be counseled carefully about the potential for increased IR rate with IOERT. Second cancer incidence and cardiac events did not differ between IOERT and WBI.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. De Rose F, Mussari S, Di Brina L, et al. Whole Breast Irradiation Versus Intraoperative Electron Radiation Therapy for Breast Conserving Therapy: A Large Mature Single Institution Matched-Pair Evaluation of True Local Relapse, Progression Free Survival, and Overall Survival. Int J Radiat Oncol Biol Phys. 2023. PMID: 36736632. doi:10.1016/j.ijrobp.2023.01.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。